Latest news with #Cencora
Yahoo
4 days ago
- Business
- Yahoo
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cencora (COR) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out. Cencora is one of 995 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Cencora is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for COR's full-year earnings has moved 2.9% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. According to our latest data, COR has moved about 29.6% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 5.3% on average. As we can see, Cencora is performing better than its sector in the calendar year. Another Medical stock, which has outperformed the sector so far this year, is Catalyst Pharmaceutical (CPRX). The stock has returned 19.6% year-to-date. The consensus estimate for Catalyst Pharmaceutical's current year EPS has increased 2.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Cencora belongs to the Medical Services industry, a group that includes 58 individual stocks and currently sits at #68 in the Zacks Industry Rank. Stocks in this group have lost about 3.9% so far this year, so COR is performing better this group in terms of year-to-date returns. Catalyst Pharmaceutical, however, belongs to the Medical - Drugs industry. Currently, this 161-stock industry is ranked #55. The industry has moved -1.8% so far this year. Investors interested in the Medical sector may want to keep a close eye on Cencora and Catalyst Pharmaceutical as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cencora, Inc. (COR) : Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Cencora, Inc. COR is well-poised for growth on the back of a robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #2 (Buy) company have risen 29.4% so far this year against the industry's 4.7% decline. The S&P 500 Index has decreased 0.3% in the same time frame. Cencora is one of the world's largest pharmaceutical service companies. It is focused on providing drug distribution and related services to reduce healthcare costs and improve patient outcomes. The company has a market capitalization of $56.05 billion. COR's bottom line is anticipated to improve 12.8% over the next five years. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6%. Image Source: Zacks Investment Research Strong performance in its U.S. Healthcare Solutions segment, particularly in specialty products and GLP-1 medications, is likely to continue to drive growth in 2025. COR and its peers are expanding into the high-margin sector as demand for medicines treating complex conditions, such as rheumatoid arthritis and cancer, continues to grow. The company posted robust second-quarter fiscal 2025 results, with earnings per share (EPS) of $4.42 (up 16.3% year over year) and revenues of $75.45 billion (up 10.3%). Internationally, revenues rose 5.7% at constant currency, supported by the European and Canadian markets. However, the International segment's operating income declined due to lower operating income at COR's global specialty logistics business, partially offset by an increase in its European distribution business. For fiscal 2025, adjusted EPS is estimated to be in the range of $15.70-$15.95 (up from the previous projection of $15.25-$15.55), indicating growth of 14-16% from the prior-year level. The top line is projected to rise 8-10%. Revenues from the U.S. Healthcare Solutions segment and the International Healthcare Solutions business are estimated to increase 9-11% and 3-4%, respectively. Adjusted operating income is expected to improve 13.5-15.5% for fiscal 2025, up from the earlier guidance of 11.5-13.5%. Cencora also acquired Retina Consultants of America earlier this year, expanding its specialty capabilities beyond oncology. This acquisition complements COR's pharmaceutical-centric strategy, strengthens its Management Services Organization portfolio and positions it well in the growing retina and ophthalmology market. Meanwhile, Cencora's focus on specialty pharmaceuticals remains a significant growth driver. Increasing demand for GLP-1 products and specialty distribution to physicians and health systems support strong revenue momentum. Investments in distribution infrastructure and technology improve logistics support and temperature-sensitive product handling and enhance compliance with regulatory standards. Investments in automation and continuity within COR's European and Canadian businesses ensure resilience and scalability in international markets. Renewed collaborations with Express Scripts and Walgreens strengthen core distribution capabilities and align resources to meet customer needs effectively. Cencora operates in a highly competitive pharmaceutical distribution and related healthcare services market. The generic industry is facing the consolidation of customers and manufacturers, global competitors and regulatory challenges. Higher sales of low-margin GLP-1 products and declining COVID-related revenues compress profit margins. Changes in U.S. healthcare policy, particularly Medicare Part B and D reimbursement reforms, could adversely impact profitability. A goodwill impairment on PharmaLex reflects underperformance in outsourced pharma services due to market pressures. Increasing competition in specialty and biosimilar markets may challenge market share and pricing strategies. Cencora, Inc. price | Cencora, Inc. Quote COR has been witnessing a positive estimate revision trend for fiscal 2025. In the past 60 days, the Zacks Consensus Estimate for earnings has increased from $15.28 to $15.36 per share. The consensus mark for second-quarter fiscal 2025 revenues is pegged at $74.64 billion, indicating a 9.1% improvement from the year-ago reported actuals. The bottom-line estimate is pinned at $4.07, implying year-over-year growth of 7.1%. Some other top-ranked stocks from the same medical industry are GENEDX HOLDINGS WGS, CVS Health CVS and CoDiagnostics CODX. GENEDX, sporting a Zacks Rank #1 (Strong Buy) at present, has an estimated growth rate of 336% for 2025. You can see the complete list of today's Zacks #1 Rank stocks here. WGS' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 145.82%. WGS' shares have lost 6.1% so far this year. CVS Health, carrying a Zacks Rank #2 at present, has an estimated growth rate of 12.2% for 2025. CVS' earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 18.08%. CVS' shares have risen 42% year to date. CoDiagnostics, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 45.2% for 2025. CODX's earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 12.72%. Its shares have lost 61.6% so far this year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Co-Diagnostics, Inc. (CODX) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28-05-2025
- Business
- Business Wire
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. 'Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value,' said Mark Durcan, Lead Independent Director. 'Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and build on our leadership as an end-to-end healthcare services provider,' said Robert P. Mauch, President and Chief Executive Officer of Cencora. Ms. Ryerkerk is the former Chairman, President and Chief Executive Officer of Celanese. She joined Celanese in 2019 and became Chairman in 2020. Prior to her role with Celanese, Ms. Ryerkerk spent over 25 years in manufacturing operations leadership roles, including Executive Vice President of Global Manufacturing at Shell Downstream Inc. She also currently serves on the Board of Directors of Eaton Corp. and Norfolk Southern. Ms. Ryerkerk earned her B.S. in Chemical Engineering from Iowa State. About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue. Learn more at
Yahoo
19-05-2025
- Business
- Yahoo
Robust Results Lifted Cencora (COR) Amid Upgraded Outlook
TimesSquare Capital Management, an equity investment management company, released its 'U.S. Focus Growth Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The broad-based downturn in US equities underperformed overseas markets in the first quarter. In this negative environment, the strategy outperformed the index in the first quarter. The strategy returned 2.42% (gross) and 2.20% (net) compared to a -7.12% return for the Russell Midcap Growth Index. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products distributor. The one-month return of Cencora, Inc. (NYSE:COR) was 3.22%, and its shares gained 31.32% of their value over the last 52 weeks. On May 16, 2025, Cencora, Inc. (NYSE:COR) stock closed at $290.22 per share with a market capitalization of $56.251 billion. Polen Focus Growth Strategy stated the following regarding Cencora, Inc. (NYSE:COR) in its Q1 2025 investor letter: "We benefited from Cencora, Inc. (NYSE:COR), which distributes pharmaceutical and medical products to pharmacies, hospitals, and other health care providers. Cencora's revenues and earnings each exceeded expectations, and management further increased forward guidance to reflect its business momentum. Later in the quarter, Cencora again lifted its outlook though that did not include future benefits from a recent acquisition. As its price improved by 24%, we trimmed our position." A scientist in a laboratory carefully analyzing a sample of cord blood. Cencora, Inc. (NYSE:COR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held Cencora, Inc. (NYSE:COR) at the end of the fourth quarter, compared to 45 in the third quarter. Cencora, Inc.'s (NYSE:COR) consolidated revenue in the second quarter of fiscal 2025 grew 10% to $75.5 billion. While we acknowledge the potential of Cencora, Inc. (NYSE:COR) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered Cencora, Inc. (NYSE:COR) and shared the list of stocks on Jim Cramer's radar. In Q1 2025, Carillon Eagle Mid Cap Growth Fund benefitted from Cencora, Inc.'s (NYSE:COR) strong growth and stability. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
19-05-2025
- Business
- Yahoo
Jim Cramer Highlights Cencora (COR) 'Knocked It Out of The Park'
We recently published a list of . In this article, we are going to take a look at where Cramer noted that while Cencora, Inc. (NYSE:COR) stands against other stocks that Jim Cramer discussed recently. On Wednesday's episode of Mad Money, Jim Cramer reviewed the recent developments affecting drug distribution companies and laid out why he is turning cautious on the group. He pointed out that stocks of major drug distributors have retreated from their all-time highs. 'Most of the time, that's because of vague, amorphous concerns that some type of regulatory crackdown will force them out of business or, at the very least, make them a lot less profitable.' READ ALSO Jim Cramer Put These 8 Stocks Under a Microscope Recently and Jim Cramer Commented on These 6 Natural Gas Players Cramer referenced the executive order signed by the President last week aimed at lowering drug prices, which triggered a sell-off across the drug distribution sector. He explained that the order would effectively require pharmaceutical companies to offer the U.S. government drug prices that match the lowest rates charged in other advanced economies. Cramer said the market's fear is straightforward: if drugmakers are forced to cut prices for their government customers, then drug distributors could see their margins shrink. 'The bottom line: No matter how well the drug distributors have been doing, I do not want to stick my neck out for an industry that now seems to be hated by both the Democrats and the Republicans. It seems like the only thing they agree on, doesn't it? There are so many potential winners in this market, I say, why take the risk?' For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on May 14. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey's database of over 1,000 hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). Number of Hedge Fund Holders: 58 Cramer noted that while Cencora, Inc. (NYSE:COR) 'knocked it out of the park' with its earnings report, the stock always seems to be in danger. 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Cencora… knocked it out of the park when they reported last Wednesday… Posted a slight top line miss but monster 31 cent earnings beat off of $4 [and] 11 cent basis. Cencora (NYSE:COR) distributes pharmaceutical products and provides healthcare services across global markets. The company supports providers through pharmacy operations, clinical trial assistance, and focused logistics solutions. Overall, COR ranks 5th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of COR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than COR but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
